Vivos Therapeutics
VVOS
23 hedge funds and large institutions have $631K invested in Vivos Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
45% more capital invested
Capital invested by funds: $434K → $631K (+$197K)
21% more funds holding
Funds holding: 19 → 23 (+4)
0.36% less ownership
Funds ownership: 5.5% → 5.14% (-0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$65.5K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$53.7K |
| 3 |
Two Sigma Investments
New York
|
+$53.6K |
| 4 |
Millennium Management
New York
|
+$31.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
-$75.4K |
| 2 |
TWP
Triad Wealth Partners
Lawrence,
Kansas
|
-$6.26K |
| 3 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$2.83K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.62K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$8 |
VVOS Hedge Fund Activity: Q3 2024 in Review
23 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2024, worth a combined $631K — up 45% from $434K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VVOS positions and 2 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was OMERS Administration Corp, opening a new position worth an estimated $65.5K. The largest seller was Strategic Wealth Investment Group, cutting an estimated $75.4K.
- 23 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2024, up from 19 in Q2 2024.
- Funds reported $631K of Vivos Therapeutics stock for Q3 2024, up 45% quarter-over-quarter.
- 6 funds opened new Vivos Therapeutics positions in Q3 2024 and 2 closed out, a net change of +4 holders.
- The largest Vivos Therapeutics buyer in Q3 2024 was OMERS Administration Corp, an estimated $65.5K added.
- The largest Vivos Therapeutics seller in Q3 2024 was Strategic Wealth Investment Group, an estimated $75.4K sold.
Based on aggregated 13F filings for Q3 2024.